Pharmacological interventions for schizoid personality disorder

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Farooq, Saeed ^a   Völlm, Birgit A ^b   Stoffers, Jutta M ^c   Gibbon, Simon ^d   Duggan, Conor ^b   Ferriter, Michael ^e   Dennis, Jane A ^f   Lieb, Klaus ^c  

^a STAFFORDSHIRE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d NOTTINGHAMSHIRE HEALTHCARE NHS TRUST   (United Kingdom)

^e RAMPTON HOSPITAL   (United Kingdom)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PRIORITY JOURNAL; RETRACTED ARTICLE;

EID: 84863787764     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009048.pub2     Document Type: Article

References (41)

1. Alltman DG, Bland JM. Detecting skewedness from summary information. BMJ 1996;313(7066):1200.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th Edition. Washington, DC: American Psychiatric Association, 1994.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
4. American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry 2001;158(Supplement 2/2):1-52.
5. Beck AT, Freeman A. Cognitive Therapy of Personality Disorders. New York: The Guilford Press, 1990.
6. Joint Formulary Committee. British National Formulary: 59.0. London: British Medical Association and Royal Pharmaceutical Society, 2010 [March].
7. Cloninger CR. A systematic method for clinical description and classification of personality variants. Archives of General Psychiatry 1987;44:573-88.
8. Cloninger CR, Svrakic DM, Pryzbeck TR. A psychobiological model of temperament and character. Archives of General Psychiatry 1993;50:975-90.
9. Coid J. Epidemiology, public health and the problem of personality disorder. The British Journal of Psychiatry 2003;182:s3-s10.
10. Costa PT, McCrae RR. NEO PI-R Professional Manual. Odessa, FL: Psychological Assessment Resources, 1992.
11. Derogatis LR. SCL-90-R, Brief Symptom Inventory, and matching clinical rating scales. In: Maruish M editor(s). Psychological Testing, Treatment Planning and Outcome Assessment. New York, NY: Erlbaum, 1994.
12. Donner A, Koval JJ. The estimation of intraclass correlation in the analysis of family data. Biometrics 1980;36:19-25.
13. Drake RE, Adler DA, Vaillant GE. Antecedents of personality disorders in a community sample of men. Journal of Personality Disorder 1988;2:60-8.
14. Duggan C, Huband N, Smailagic N, Ferriter M, Adams C. The use of psychological treatments for people with personality disorder: a systematic review of randomized controlled trials. Journal of Personality and Mental Health 2007;1:95-125.
15. Duggan C, Huband N, Smailagic N, Ferriter M, Adams C. The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials. Journal of Personality and Mental Health 2008;2:119-70.
16. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
17. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vaillancourt JM. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
18. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976;33:766-71.
19. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured clinical interview for DSM-IV Axis II personality disorders (SCID-II). Washington, DC: American Psychiatric Press, 1997.
20. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for the overviews of clinical trials with continuous response. Journal of Clinical Epidemilogy 1992;45:769-73.
21. Gamble C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58:579-88.
22. Guy W. ECDEU Assessment Manual for Psychoparmacology-Revised. DHEW Publ No ADM 76-338. Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:218-22.
23. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009]. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
24. Hyler SE. Personality Diagnostic Questionnaire-4. New York, NY: New York State Psychiatric Institute, 1994.
25. Lenzenweger MF, Loranger AW, Korfine L, Neff C. Detecting personality disorders in a nonclinical population. Archives of General Psychiatry 1997;54:345-51.
26. Livesley WJ, Jang KL, Jackson DN, Vernon PA. Genetic and environmental contributions to dimensions of personality disorder. American Journal of Psychiatry 1993;150:1826-31.
27. Maier W, Lichtermann D, Klingler T, Heun R, Hallmayer J. Prevalences of personality disorders (DSM-III-R) in the community. Journal of Personality Disorder 1992;6:187-96.
28. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al.Randomized, double-blind trial of olanzapine vs placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry 2006;163(5):790-9.
29. McGorry PD, Phillips LJ, Nelson B, Leicester S, Baker K, Krstev H, et al.A double-blind, placebo-controlled randomized trial of low-dose risperidone, cognitive-behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six-month outcome data. Schizophrenia Bulletin 2007;33 (supplement):446.
30. Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-IV Personality Disorders. Washington, DC: American Psychiatric Press, 1997.
31. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
32. Siever LJ, Davis KI. A psychobiologic perspective on the personality disorders. American Journal of Psychiatry 1991;148:1647-58.
33. Sievwright H, Tyrer P, Johnson T. Change in personality status in neurotic disorders. The Lancet 2002;359:2253-4.
34. Skodol AE, Gunderson JG, McGlashan TH, Dyck IR, Stout RL, Bender DS, et al.Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. American Journal of Psychiatry 2002;159:276-83.
35. Soloff PH. Algorithms for pharmacological treatment of personality dimensions. Symptom-specific treatments for cognitive/perceptual, affective, and impulsive/behavioral dysregulation. Bulletin of the Menninger Clinic 1998;62:195-214.
36. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Archives of General Psychiatry 2001;58:590-6.
37. Tyrer P, Gunderson J, Lyons M, Tohen M. Extent of comorbidity between mental state and personality disorders. Journal of Personality Disorders 1997;11:242-59.
38. Tyrer P, Nur U, Crawford M. The Social Functioning Questionnaire: a rapid and robust measure of perceived functioning. International Journal of Social Psychiatry 2005;51:265-75.
39. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organisation based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92.
40. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Archives of General Psychiatry 1976;33:1111-5.
41. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. 10th Edition. Geneva: World Health Organization, 1992.